50% recruitment reached for Phase II prostate cancer trial
Filed with ASX · · 3 pages · English
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce 64 the Phase II diagnostic Cu SAR-Bombesin trial (BOP) for patients with prostate cancer has reached the fifty percent recruitment milestone, with 15 out of 30 part
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Corporate Presentation - Wilsons Drug and Device Conference
- 50% recruitment milestone reached for prostate cancer trial
- First patient treated in therapeutic prostate cancer trial
- First participant imaged in Phase II SAR-Bombesin trial
- First participants imaged in SAR-Bombesin trial
Later from Clarity Pharmaceuticals
- Clarity Presentation -Bell Potter Healthcare Conference 2022
- IND approval from the FDA for theranostic SAR-Bombesin trial
- Chairmans Address to Shareholders
- Managing Directors Presentation to AGM
- Positive topline results from SAR-bisPSMA diagnostic trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals